Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KYNU | Q16719 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484062 | 0.80 | NPSR1 (0.40) | CASP1ALDH1A1NPSR1RBP4 | |
| SCHEMBL9929726 | 0.78 | CTSK (0.41) | — | |
| SCHEMBL1484229 | 0.69 | GRIK1 (0.36) | — | |
| SCHEMBL8402490 | 0.66 | NFKB1 (0.56) | NFKB1 | |
| SCHEMBL818741 | 0.66 | NFKB1 (0.56) | NFKB1 | |
| SCHEMBL8529144 | 0.65 | NFKB1 (0.50) | ALDH1A1NFE2L2NFKB1 | |
| SCHEMBL8576453 | 0.65 | ALDH1A1 (0.48) | ALDH1A1NFE2L2KIF11NFKB1 | |
| SCHEMBL22026727 | 0.64 | NFKB1 (0.68) | ALDH1A1NPSR1NFE2L2CYP1A2NFKB1 | |
| SCHEMBL1396433 | 0.64 | GRIK1 (0.38) | CASP1KIF11CYP1A2KYNU | |
| SCHEMBL9942127 | 0.64 | GRIK1 (0.38) | CASP1PTGS1KIF11CYP1A2KYNU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| EP-2288615-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | New World Laboratories Inc. (CA) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009140765-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | CASP1 1/4885PTGES2 3278/4885ALDH1A1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.